Sonic Healthcare Limited (SAB) AI Stock Analysis

3 Followers

Sonic Healthcare Limited

(Frankfurt:SAB)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Resilient revenue and advanced diagnostics growthRecurring demand for pathology and imaging, supported by healthcare utilization and specialized testing, provides a durable growth base. Strong advanced diagnostics performance also indicates improving service mix and opportunities beyond routine testing.

Negative Factors

Structural margin compression and weaker returnsThe sustained decline from prior profitability peaks suggests cost, reimbursement or business-mix pressure rather than a temporary fluctuation. Lower margins and a 7.3% return on equity reduce earnings resilience and limit operating leverage.

Sonic Healthcare Limited (SAB) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 9.82B
Dividend Yield: 5.49%
Average Volume (3M): 567
Price to Earnings (P/E): 16.2
Beta (1Y): 0.42
Revenue Growth: 11.83%
EPS Growth: 13.23%
Country: Germany
Employees: 47,000
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Diagnostics & Research

Sonic Healthcare Limited Business Overview & Revenue Model

Company Description

Sonic Healthcare Limited delivers medical diagnostic services to a diverse clientele, including medical professionals, hospitals, public health organizations, and individual patients. The company's services encompass a broad spectrum of laboratory me...

Sonic Healthcare Limited Earnings Call Summary

Earnings Call Date:Aug 19, 2026(Q4-2026)|% Change Since:-12.90%|Next Earnings Date:Feb 22, 2027

Earnings Call SentimentPositive

The call conveyed a largely positive operational and financial picture: strong FY2026 headline results (13% revenue growth, 11% EBITDA growth, 17% NPAT growth), clear progress on acquisitions and synergy capture (notably LADR), solid organic and advanced diagnostics growth, and active capital management. Notable challenges were highlighted—regulatory fee cuts in Switzerland (~CHF 20m), integration and labor cost pressures in the U.K., legacy software impairments (AUD 83m), U.S. market headwinds and uncertainty over potential PAMA cuts, and elevated FY2026 capex and interest costs. Management has provided FY2027 guidance that factors in many of these headwinds and set out remediation initiatives (U.S. operating review, continued synergy capture, digital transformation). On balance, the positives (growth, acquisitions performing, synergy delivery, strong cash/capital actions) outweigh the identified headwinds, although risks remain in specific markets and from regulatory/FX exposures.

Positive Updates

Strong FY2026 Financial Performance

Total revenue up 13% to AUD 10.867 billion; EBITDA up 11% to AUD 1.933 billion (AUD 1.916 billion constant currency); net profit after tax up 17% to AUD 621 million; EPS up 14% to AUD 1.26. FY2026 underlying results in line with guidance.

Negative Updates

Regulatory Fee Reductions in Switzerland

Regulatory changes effective 1 July 2026 expected to reduce FY2027 revenue by an estimated CHF 20 million (approximately 3% of Switzerland revenue). This is a direct top-line and margin headwind for FY2027.

Company Guidance

Sonic guided FY2027 constant‑currency underlying EBITDA of AUD 1.95–2.03 billion (excluding ~AUD 30 million of back‑office IT transformation costs), with depreciation expected at AUD 810–825 million, amortisation AUD 90–95 million, interest expense up ~6% versus FY2026 and an effective tax rate of ~27%; the guidance excludes potential PAMA fee cuts in the U.S., any property sale gains and assumes no further regulatory changes and current interest rates. Management expects the U.S. operating review to add ~AUD 25–30 million to FY2027 earnings, flagged a Switzerland regulatory revenue impact of CHF 20 million (≈3% of revenue) for FY2027, noted a potential FX EBITDA headwind of ~AUD 40–50 million at current spot rates, expects maintenance CapEx to remain around ~3% of revenue (FY2026 maintenance CapEx ~AUD 351 million) with total PP&E CapEx falling from FY2026’s AUD 631 million as major projects complete, and reiterated capital discipline with a debt cover ratio of 2.2, ~AUD 1.6 billion headroom (pre‑final dividend) and a medium‑term dividend payout target of 70–80% of net profit.

Sonic Healthcare Limited Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:SAB against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AU:ACL	54Neutral	AUD 606.19M	26.66	15.80%	3.92%	-0.90%	-25.09%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AU:HLS	51Neutral	AUD 384.87M	-0.94	-114.08%	―	2.16%	21.05%
AU:IDX	48Neutral	AUD 640.52M	28.83	3.24%	5.88%	25.73%	390.83%
AU:BDX	39Underperform	AUD 23.60M	-3.03	-881.94%	―	743.51%	-1.52%
AU:GSS	39Underperform	AUD 17.49M	-1.17	-35.10%	―	-9.10%	31.75%

* Healthcare Sector Average

Performance Comparison

DE:SAB and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:SAB	Sonic Healthcare Limited	11.97	0.75	6.71%
AU:HLS	Healius Limited	0.53	-0.37	-41.34%
AU:BDX	BCAL Diagnostics Limited	0.06	-0.02	-20.00%
AU:GSS	Genetic Signatures Ltd.	0.07	-0.23	-76.00%
AU:IDX	Integral Diagnostics Ltd.	1.70	-0.76	-30.89%
AU:ACL	Australian Clinical Labs Ltd	3.32	0.76	29.94%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Sonic Healthcare Limited AI Stock Analysis